Kimball Electronics delivers a package of value that includes durable, high-reliability electronics, higher level and final assemblies, and contract manufacturing organization solutions. The company provides engineering and supply chain support for the production of electronic assemblies and other products, including medical devices, medical disposables, and precision molded plastics. Kimball Electronics serves customers primarily in automotive, medical, and industrial…
Kimball Electronics delivers a package of value that includes durable, high-reliability electronics, higher level and final assemblies, and contract manufacturing organization solutions. The company provides engineering and supply chain support for the production of electronic assemblies and other products, including medical devices, medical disposables, and precision molded plastics. Kimball Electronics serves customers primarily in automotive, medical, and industrial applications across its global manufacturing footprint.
Kimball Electronics generates revenue through contract manufacturing services, including production and testing of printed circuit board assemblies, high-level and final assembly of medical, automotive, and industrial products, design services and support, supply chain services, rapid prototyping, new product introduction support, product design and process validation, industrialization and automation of manufacturing processes, reliability testing, aftermarket services, production and assembly of medical devices and medical disposables, drug delivery devices with and without electronics, Class 7 and 8 clean room assembly, cold chain and product sterilization management, design engineering and production of precision molded plastics, and complete product life cycle management. The company markets its services globally via its business development team and customer relationship management model, offering convenient access to its integrated global footprint and standardized operating systems throughout the entire product life cycle.
The company operates through the following segments:
• Contract Manufacturing: This segment provides engineering and supply chain support for the production of electronic assemblies and other products, including medical devices, medical disposables, and precision molded plastics, to the specifications and designs of customers. The segment serves customers in automotive, medical, and industrial end markets. Kimball Electronics offers services such as production and testing of printed circuit board assemblies, high-level and final assembly, design for excellence solutions, supply chain management, rapid prototyping, new product introduction support, product design and process validation, industrialization and automation, reliability testing, aftermarket services, medical device and disposable assembly, drug delivery solutions, Class 7 and 8 clean room assembly, cold chain management, product sterilization, precision molded plastics design and production, and complete product life cycle management.
Kimball Electronics competes in the global electronics manufacturing services industry against companies such as Benchmark Electronics, Inc., Flex Ltd., Jabil Inc., Plexus Corp., and Sanmina Corporation. The company was ranked the 24th largest global EMS provider for calendar year 2024 by Manufacturing Market Insider in the March 2025 edition published by New Venture Research. Kimball Electronics derives its competitive strengths from 40 years of experience producing safety-critical electronic assemblies for automotive customers, which it leverages to deliver innovative solutions across industries, supported by its highly integrated global footprint, fully integrated engineering and supply chain services, customer relationship management model, customer scorecard process, quality systems, industry certifications, regulatory compliance, integrated supply chain solutions, competitive bid processes, and complete product life cycle management capabilities.
Kimball Electronics serves customers concentrated in the automotive, medical, and industrial end markets. Sales by industry as a percent of net sales for the year ended June 30, 2025 were 49% automotive, 27% medical, and 24% industrial. Included in sales were significant amounts to Nexteer Automotive, Philips, and ZF, which accounted for 19%, 14%, and 11% of net sales, respectively, for the year ended June 30, 2025. The company’s customer agreements are often not for a definitive term and are amended and extended, but generally continue for the relevant product’s life cycle, with customers typically having the right to cancel a program subject to contractual provisions.
Sector:TechnologySector rationaleKimball Electronics operates as an Electronics Manufacturing Services (EMS) provider, specifically offering contract manufacturing, production and testing of printed circuit board assemblies, and electronic assemblies. According to the sector definitions, Electronic Manufacturing Services is explicitly listed under the Technology sector.Industry:Electronic Manufacturing ServicesTechnologyPrimaryKimball Electronics operates as a contract manufacturing organization (CMO) providing printed circuit board assembly, high-level and final assembly, and box build services for other brands. It explicitly competes in the global electronics manufacturing services (EMS) industry and serves OEMs in the automotive, medical, and industrial sectors.Classified using BQ-MICSCIK: 0001606757
Investment Thesis
▲ Bull case
The medical vertical is showing robust underlying momentum with normalized year over year sales growth of 17% and sequential growth of 10% marking three consecutive quarters of double digit expansion. Growth in Asia exceeded 20% in the quarter reflecting the export strength of the Thailand facility and aligning with global outsourcing trends for drug delivery and diagnostic devices. Management’s target of adding five new medical customers per year is on track and the Indianapolis CMO facility is slated to begin production before year end providing additional capacity to accommodate these new logos and lift and shift opportunities. The combination of organic customer wins and active tuck in M&A discussions positions the medical segment to become a larger share of total revenue and to drive margin expansion once the fixed cost base is absorbed by higher volume.
The balance sheet remains strong with cash of $14.9 million and a renewed $300 million revolver providing $358.5 million of total liquidity giving the company ample dry powder to fund capex working capital needs and potential acquisitions. Operating cash flow has been positive for nine consecutive quarters and cash conversion days improved to 90 days down nine days year over year reflecting tighter working capital management and reduced inventory which fell $23.3 million or eight% year over year. Capital expenditures are guided to $50 million to $60 million for the full year with most of the spend directed to leasehold improvements at the Indianapolis facility and scaling new programs in Europe keeping investment focused on growth initiatives. Share repurchases continue with $4 million deployed this quarter and $6.5 million remaining under the authorization demonstrating confidence in intrinsic value while still leaving cash for strategic uses.
Geographic diversification provides a buffer against regional weakness with Europe showing strong automotive growth of 20% in Poland and Romania and the industrial segment seeing a rebound in public safety and smart meter sales in that region. The automotive vertical while pressured by lower demand for electronic steering in North America due to legislative changes remains well positioned for next generation braking and steering programs and could benefit if macroeconomic conditions improve or if higher gasoline prices renew consumer interest in EV platforms. The industrial segment’s offsetting strengths in public safety and smart meters coupled with an ongoing recovery in Europe suggest the near term decline may be more cyclical than structural. Overall the company’s mix of North America Asia and Europe each representing roughly one third of sales reduces reliance on any single market and supports steady top line performance.
Management commentary indicates that pricing in the medical CMO space remains aggressive fair but still rational supported by the need for multiple suppliers in the supply chain which should limit margin erosion from competitive bidding. The effective tax rate is expected to fall to approximately 30% for the full fiscal year down from 34.9% in the quarter and from 46.6% a year ago providing a modest boost to net income. Guidance for fiscal 2026 has been affirmed with revenue of $1.4 billion to $1.46 billion and adjusted operating income margin expected at the high end of the 4.2% to 4.5% range implying Q4 sales of $370 million to $380 million and margin of 4.4% to 4.6%. The company’s track record of nine straight quarters of positive operating cash flow and improving working capital metrics demonstrates operational discipline that can sustain growth even in a modest macro environment.
The medical vertical is showing robust underlying momentum with normalized year over year sales growth of 17% and sequential growth of 10% marking three consecutive quarters of double digit expansion. Growth in Asia exceeded 20% in the quarter reflecting the export strength of the Thailand facility and aligning with global outsourcing trends for drug delivery and diagnostic devices. Management’s target of adding five new medical customers per year is on track and the Indianapolis CMO facility is slated to begin production before year end providing additional capacity to accommodate these new logos and lift and shift opportunities. The combination of organic customer wins and active tuck in M&A discussions positions the medical segment to become a larger share of total revenue and to drive margin expansion once the fixed cost base is absorbed by higher volume.
The balance sheet remains strong with cash of $14.9 million and a renewed $300 million revolver providing $358.5 million of total liquidity giving the company ample dry powder to fund capex working capital needs and potential acquisitions. Operating cash flow has been positive for nine consecutive quarters and cash conversion days improved to 90 days down nine days year over year reflecting tighter working capital management and reduced inventory which fell $23.3 million or eight% year over year. Capital expenditures are guided to $50 million to $60 million for the full year with most of the spend directed to leasehold improvements at the Indianapolis facility and scaling new programs in Europe keeping investment focused on growth initiatives. Share repurchases continue with $4 million deployed this quarter and $6.5 million remaining under the authorization demonstrating confidence in intrinsic value while still leaving cash for strategic uses.
Geographic diversification provides a buffer against regional weakness with Europe showing strong automotive growth of 20% in Poland and Romania and the industrial segment seeing a rebound in public safety and smart meter sales in that region. The automotive vertical while pressured by lower demand for electronic steering in North America due to legislative changes remains well positioned for next generation braking and steering programs and could benefit if macroeconomic conditions improve or if higher gasoline prices renew consumer interest in EV platforms. The industrial segment’s offsetting strengths in public safety and smart meters coupled with an ongoing recovery in Europe suggest the near term decline may be more cyclical than structural. Overall the company’s mix of North America Asia and Europe each representing roughly one third of sales reduces reliance on any single market and supports steady top line performance.
Management commentary indicates that pricing in the medical CMO space remains aggressive fair but still rational supported by the need for multiple suppliers in the supply chain which should limit margin erosion from competitive bidding. The effective tax rate is expected to fall to approximately 30% for the full fiscal year down from 34.9% in the quarter and from 46.6% a year ago providing a modest boost to net income. Guidance for fiscal 2026 has been affirmed with revenue of $1.4 billion to $1.46 billion and adjusted operating income margin expected at the high end of the 4.2% to 4.5% range implying Q4 sales of $370 million to $380 million and margin of 4.4% to 4.6%. The company’s track record of nine straight quarters of positive operating cash flow and improving working capital metrics demonstrates operational discipline that can sustain growth even in a modest macro environment.
The new Indianapolis medical facility is expected to weigh on gross margin with a projected 40 to 50 basis point impact in fiscal 2027 as fixed costs are incurred before sufficient revenue is generated to absorb them. Management noted that the margin drag will persist until fiscal 2028 when higher volume is expected to start covering the expense. This near term headwind could offset the benefits of medical segment growth and keep overall profitability below historical levels. Investors should watch the ramp up schedule and any delays in customer qualification that could prolong the margin pressure.
Automotive sales are being held back by reduced demand for electronic steering in North America following legislative changes that cut EV incentives and the company has acknowledged that demand for awarded programs has not met expectations. While Europe showed growth of 20% in Poland and Romania the declines in Asia and North America outweigh that strength leaving the vertical down three% year over year. The segment’s performance remains tightly linked to macroeconomic factors such as gasoline prices and consumer sentiment which could keep the recovery uncertain. If the macro environment does not improve the automotive vertical may continue to be a drag on consolidated results.
Industrial results were hurt by lower demand for HVAC systems in North America and the public safety and smart meter offset may be threatened by a protracted war in the Middle East that could disrupt European demand for those products. The company noted that the near term outlook for the industrial segment could be affected by geopolitical instability adding another layer of uncertainty beyond the cyclical HVAC downturn. Inventory reductions of eight% year over year may reflect destocking rather than underlying demand strength raising questions about the sustainability of the recent working capital improvements. Continued reliance on inventory drawdowns to boost cash flow could limit the ability to support future production increases.
Selling general and administrative expenses rose to 3.7% of sales from 3% a year ago as the company invests in business transformation and IT initiatives and if revenue growth does not keep pace this higher cost base could compress operating margins. The company’s ability to add five new medical customers per year is a key assumption for future growth and any shortfall in new logo acquisition would directly affect the top line and the utilization of the Indianapolis facility. While the balance sheet shows improvement with debt down about nine% year over year the revolver renewal provides liquidity but the absolute cash position remains modest at $14.9 million leaving little buffer for unexpected costs or capex overruns. Share repurchases of $4 million this quarter use cash that could alternatively be directed toward debt reduction or growth investments.
The new Indianapolis medical facility is expected to weigh on gross margin with a projected 40 to 50 basis point impact in fiscal 2027 as fixed costs are incurred before sufficient revenue is generated to absorb them. Management noted that the margin drag will persist until fiscal 2028 when higher volume is expected to start covering the expense. This near term headwind could offset the benefits of medical segment growth and keep overall profitability below historical levels. Investors should watch the ramp up schedule and any delays in customer qualification that could prolong the margin pressure.
Automotive sales are being held back by reduced demand for electronic steering in North America following legislative changes that cut EV incentives and the company has acknowledged that demand for awarded programs has not met expectations. While Europe showed growth of 20% in Poland and Romania the declines in Asia and North America outweigh that strength leaving the vertical down three% year over year. The segment’s performance remains tightly linked to macroeconomic factors such as gasoline prices and consumer sentiment which could keep the recovery uncertain. If the macro environment does not improve the automotive vertical may continue to be a drag on consolidated results.
Industrial results were hurt by lower demand for HVAC systems in North America and the public safety and smart meter offset may be threatened by a protracted war in the Middle East that could disrupt European demand for those products. The company noted that the near term outlook for the industrial segment could be affected by geopolitical instability adding another layer of uncertainty beyond the cyclical HVAC downturn. Inventory reductions of eight% year over year may reflect destocking rather than underlying demand strength raising questions about the sustainability of the recent working capital improvements. Continued reliance on inventory drawdowns to boost cash flow could limit the ability to support future production increases.
Selling general and administrative expenses rose to 3.7% of sales from 3% a year ago as the company invests in business transformation and IT initiatives and if revenue growth does not keep pace this higher cost base could compress operating margins. The company’s ability to add five new medical customers per year is a key assumption for future growth and any shortfall in new logo acquisition would directly affect the top line and the utilization of the Indianapolis facility. While the balance sheet shows improvement with debt down about nine% year over year the revolver renewal provides liquidity but the absolute cash position remains modest at $14.9 million leaving little buffer for unexpected costs or capex overruns. Share repurchases of $4 million this quarter use cash that could alternatively be directed toward debt reduction or growth investments.